ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Prediction of Hypertension Risk in Patients with Fatty Liver Disease Using the Triglyceride-Glucose-Body Mass Index.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between blood lipid levels, BMI, and hypertension among employees in petrochemical enterprises.Frontiers in cardiovascular medicine · 2026Article
- Association between the triglyceride-glucose index and hypertension: potential role of fatty liver in a cross-sectional study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Fatty liver disease (FLD) and hypertension (HTN) exhibit a bidirectional relationship: FLD elevates HTN risk, while HTN accelerates FLD progression to fibrosis. Research on this link is limited, with insulin resistance (IR) proposed as a key mechanism. The triglyceride-glucose-body mass index (TyG-BMI), an emerging IR marker, is poorly characterized regarding its association with FLD and HTN. This study assessed TyG-BMI's predictive value for HTN risk in FLD patients and its clinical significance. Patients and Methods: A retrospective cohort of 6,257 FLD patients confirmed by ultrasonography from the Health Examination Center of Chengde Medical University was analyzed. Participants were categorized into FLD-HTN (n=2,804) and normotensive FLD (FLD-0, n=3,453) groups based on blood pressure measurements. Multivariable logistic regression models adjusted for confounders assessed TyG-BMI's independent association with HTN risk. Receiver operating characteristic (ROC) curve analysis, with DeLong's test, compared the discriminative ability of TyG-BMI against conventional indices (BMI and TyG index). Additionally, quartile-based stratification (Q1-Q4) further explored dose-response relationships. Results: Multivariable-adjusted models showed a 1.6% increase in HTN risk for each unit increase in TyG-BMI (OR=1.016, 95% CI: 1.014-1.018, Conclusion: TyG-BMI is a significant predictor of HTN risk in FLD patients, offering a clinically useful tool for targeted prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.